Skip to main content
    H

    Humacyte Inc (HUMA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.50
    -0.04 (-7.27%)

    Market Cap: $155.12M

    Last updated: Nov 17, 2026 at 4:28 PM ET

    Humacyte Inc (HUMA) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Humacyte (HUMA) has a market cap of $155.12M and an enterprise value of $156.47M. It kept -3955.05% of revenue as net income over the last 12 months. Its share count is up 75.47% from a year earlier.

    Total Valuation

    Enterprise value is 0.87% above the market cap, as debt exceeds cash.

    Market Cap$155.12M
    Enterprise Value$156.47M
    Latest price (Nov 17, 2026)$0.50

    Key Dates

    The next earnings report is expected on Mar 25, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 25, 2027 (expected)
    Last Earnings DateNov 10, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 18.62% in the quarter ended Sep 30, 2026 and grew 52.53% a year over 2 years.

    Shares Outstanding277.80M
    Shares Change (YoY)+75.47%
    Shares Change (QoQ)+18.62%
    Share Count Growth (2Y CAGR)+52.53%

    Valuation Ratios

    Sales and book value multiples are 58.1x and 7.7x. Its year-end P/S ranged from 27.3x to 138.9x from 2022 to 2025.

    P/S Ratio58.1x
    Forward P/S38.9x
    P/B Ratio7.7x

    Valuation history and multiples

    Price Statistics

    The stock is down 59.27% over 52 weeks and trades 2.04% above its 50-day average.

    Beta (1Y)2.67
    52-Week Change-59.27%
    1-Month Change+24.91%
    3-Month Change-31.83%
    6-Month Change-39.29%
    5-Year Change-95.48%
    Total Return (1Y)-59.27%
    Total Return (3Y CAGR)-41.63%
    Total Return (5Y CAGR)-46.58%
    Max Drawdown (1Y)-76.23%
    Max Drawdown (3Y)-96.26%
    Sharpe Ratio (1Y)-0.78
    Correlation with SPY (1Y)0.33
    50-Day Average$0.49
    200-Day Average$0.77
    52-Week Range$0.34 to $1.52
    RSI (14 Days)51.5
    Average Volume (20 Days)4.76M

    The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 3.34x current liabilities, and total debt is 3.65x shareholder equity.

    Current Ratio3.34x
    Quick Ratio3.11x
    Debt / Equity3.65x
    Interest Coverage-1.99x

    Returns and Efficiency

    Return on invested capital is -60.48% over the last 12 months, against a 5-year average of 47.26%.

    Return on Equity (ROE)-524.60%
    Return on Assets (ROA)-75.47%
    Return on Invested Capital (ROIC)-60.48%
    Return on Capital Employed (ROCE)-63.75%
    ROA (5Y Average)-48.89%
    ROIC (5Y Average)47.26%
    Asset Turnover0.02x
    Inventory Turnover2.14x
    Receivables Turnover4.20x
    Cash Conversion Cycle163 days

    Scores

    HUMA has an Altman Z-Score of -9.22, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score-9.22
    Altman Z ZoneDistress
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $2.40M over the last 12 months is down 72.77% from the 12 months before.

    Revenue$2.40M
    Revenue Growth (YoY)-72.77%
    Gross Profit-$11.08M
    Operating Income-$110.29M
    Pretax Income-$94.76M
    Net Income-$94.76M
    EBITDA-$56.28M
    EBIT-$64.26M
    Reported EPS (TTM)-$0.51

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 14.38% of the $125.57M in total assets.

    Cash and Equivalents$64.52M
    Total Debt$65.87M
    Net Debt$1.35M
    Net Debt Per Share$0.00
    Working Capital$57.92M
    Shareholder Equity$18.06M
    Book Value Per Share$0.07
    Total Assets$125.57M
    Total Liabilities$107.51M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$88.26M
    FCF Per Share-$0.32
    Depreciation and Amortization$7.98M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -4602.92%.

    Gross Margin-462.60%
    Operating Margin-4602.92%
    Pretax Margin-3955.05%
    Net Margin-3955.05%
    EBITDA Margin-2348.87%
    EBIT Margin-2682.10%

    Growth

    Revenue grew 9.20% a year over 3 years.

    Revenue Growth (3Y CAGR)+9.20%
    Revenue Growth (5Y CAGR)+6.45%
    Book Value Per Share Growth (2Y CAGR)-61.23%
    Tangible Book Per Share Growth (2Y CAGR)-61.23%

    Revenue and profit by year

    Dividends and Yields

    HUMA does not pay a dividend.

    Buyback Yield-95.81%
    Shareholder Yield-95.81%

    Peer Position

    Against 4 similar companies, HUMA has the highest P/S and the 3rd highest ROIC.

    P/S Ratio58.1x vs 2.1x median
    ROIC-60.48% vs -60.00% median
    Revenue Growth (Trailing 4 Quarters, YoY)-72.77% vs -100.00% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 239.15% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+239.15%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About HUMA

    What is HUMA's market cap?

    Humacyte has a market cap of $155.12M. Its enterprise value, which adds debt and subtracts cash, is $156.47M.

    How many shares of HUMA are outstanding?

    Humacyte has 277.80M shares outstanding. The count is up 75.47% from a year earlier.

    Does HUMA pay a dividend?

    No. Humacyte does not pay a dividend.

    How much debt does HUMA have?

    Humacyte has $65.87M of total debt and $64.52M of cash and equivalents, a net debt position of $1.35M.